Back
 AJAC  Vol.6 No.13 , December 2015
Stability Indicating RP-HPLC Method for Estimation of Impurities of Vitamin D3 Analogue and Corticosteroid Used as Antipsoriatic Drugs. An Attempt to Characterize Pre-Calcipotriene
Abstract: A single RP-HPLC method is developed for estimation of isomeric impurities of vitamin D3 analogue-Calcipotriol/Calcipotriene (Calci) and impurities of Betamethasone dipropionate (BD). The developed method is capable of separating impurities of Calci and BD, specifically pre-Calcipotriene (Pre-Calci) from other known and unknown impurities. Pre-Calci is isolated and is characterised using few analytical techniques. These impurities are separated using a RP-C18 150 × 4.6 mm, 2.7 μm column maintained at 50°C. The mobile phase consisted of mixture of water, methanol, acetonitrile and tetrahydrofuran eluted in gradient mode. Detection was done at 264 nm and 240 nm for Calci and BD impurities respectively. The method can be used for determining quality of Calci and BD drugs and ointment based drug products. It is stability indicating related substance method for both the drugs and drug products.
Cite this paper: Bhogadi, R. , Satyanarayana, A. , Rao, N. , Arutla, S. and Reddy, A. (2015) Stability Indicating RP-HPLC Method for Estimation of Impurities of Vitamin D3 Analogue and Corticosteroid Used as Antipsoriatic Drugs. An Attempt to Characterize Pre-Calcipotriene. American Journal of Analytical Chemistry, 6, 1050-1058. doi: 10.4236/ajac.2015.613100.
References

[1]   Thacher, S.M., Vasudevan, J., Tsang, K.Y., Nagpal, S. and Chandraratna, R.A. (2001) New Dermatological Agents for the Treatment of Psoriasis. Journal of Medicinal Chemistry, 44, 281-297.
http://dx.doi.org/10.1021/jm0000214

[2]   Darley, C.R., Cunliffe, W.J., Green, C.M., Hutchinson, P.E., Klaber, M.R. and Downes, N. (1996) Safety and Efficacy of Calcipotriolointment (Dovonex) in Treating Children with Psoriasis Vulgaris. British Journal of Dermatology, 135, 390-393.
http://dx.doi.org/10.1111/j.1365-2133.1996.tb01501.x

[3]   Dubertret, L., Wallach, D., Souteyrand, P., Perussel, M., Kalis, B., Meynadier, J., Chevrant-Breton, J., Beylot, C., Bazex, J.A. and Jurgensen, H.J. (1992) Efficacy and Safety of Calcipotriol (MC 903) Ointmentin Psoriasis Vulgaris. A Randomized, Double-Blind, Right/Left Comparative, Vehicle-Controlled Study. Journal of the American Academy of Dermatology, 27, 983-988.
http://dx.doi.org/10.1016/0190-9622(92)70299-U

[4]   Kobayashi, T., Okumura, H., Hashimoto, K., Asada, H., Inui, S. and Yoshikawa, K. (1998) Synchronization of Normal Human Keratinocyte in Culture: Its Application to the Analysis of 1,25-Dihydroxy Vitamin D3 Effects on Cell Cycle. Journal of Dermatological Science, 17, 108-114.
http://dx.doi.org/10.1016/S0923-1811(97)00081-9

[5]   Kragballe, K., Steijlen, P.M., Ibsen, H.H., van de Kerkhof, P.C., Esmann, J., Sorensen, L.H. and Axelsen, M.B. (1995) Efficacy, Tolerability, and Safety of Calcipotriol Ointment in Disorders of Keratinization. Results of a Randomized, Double-Blind, Vehicle Controlled, Right/Left Comparative Study. Archives of Dermatological Research, 131, 556-560.
http://dx.doi.org/10.1001/archderm.1995.01690170058008

[6]   Kragballe, K., Gjertsen, B.T., de Hoop, D., et al. (1991) Double Blind Right/Left Comparison of Calcipotriol (MC903) and Bethamethasone Valerate in the Treatment of Psoriasis Vulgaris. Lancet, 337, 193-196.
http://dx.doi.org/10.1016/0140-6736(91)92157-W

[7]   Kragballe, K., Barnes, L., Hamberg, K.J., Hutchinson, P., Murphy, F., Moller, S., Ruzicka, T. and van de Kerkhof, P.C. (1998) Calcipotriol Cream with or without Concurrent Topical Corticosteroid in Psoriasis: Tolerability and Efficacy. British Journal of Dermatology, 139, 649-654.
http://dx.doi.org/10.1046/j.1365-2133.1998.02461.x

[8]   Lebwohl, M., Siskin, S., Epinette, W., Breneman, D., Funicella, T., Kalb, R. and Moore, J. (1996) A Multicentertrial of Calcipotriene Ointment and Halobetasolointment Compared with Either Agent Alone for the Treatment of Psoriasis. Journal of the American Academy of Dermatology, 35, 268-269.
http://dx.doi.org/10.1016/S0190-9622(96)90349-7

[9]   Ruzicka, T. and Lorenz, B. (1998) Comparison of Calcipotriolmonotherapy and a Combination of Calcipotrioland Betamethasone Valerate after 2 Weeks’ Treatment with Calcipotriol in the Topical Therapy of Psoriasis Vulgaris: A Multicentre, Double-Blind, Randomized Study. British Journal of Dermatology, 138, 254-258.
http://dx.doi.org/10.1046/j.1365-2133.1998.02070.x

[10]   Lebwohl, M. (1997) Topical Application of Calcipotriene and Corticosteroids: Combination Regimens. Journal of the American Academy of Dermatology, 37, S55-S58.

[11]   PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands EU. Procedure Number: NL/H/1267/001/DC.

[12]   PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands EU. Procedure Number: NL/H/0730/001/DC.

[13]   CDER Approval Package for Application Number 020611, Product Inadequate Information and Deficiencies Dovonex Scalp Solution 0.005% BMS Pharmaceutical Reach Institute.

[14]   European Pharmacopeia 7.7.

 
 
Top